Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23771434)

1.

Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine.

Witherspoon M, Chen Q, Kopelovich L, Gross SS, Lipkin SM.

Cancer Discov. 2013 Sep;3(9):1072-81. doi: 10.1158/2159-8290.CD-12-0305. Epub 2013 Jun 14.

2.
3.

AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.

Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Sholler G.

Int J Cancer. 2013 Sep 15;133(6):1323-33. doi: 10.1002/ijc.28139. Epub 2013 May 30.

PMID:
23457004
5.
6.
7.

Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells.

Selamnia M, Mayeur C, Robert V, Blachier F.

Biochem Pharmacol. 1998 Apr 15;55(8):1241-5.

PMID:
9719479
9.

Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.

Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW.

Biochem J. 2003 Oct 15;375(Pt 2):465-70.

10.

Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

Meyskens FL Jr, Gerner EW.

Clin Cancer Res. 1999 May;5(5):945-51. Review.

11.

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):989-92.

12.
13.

Effects of alpha-difluoromethylornithine on the cyclin A expression in Hep-2 cells.

Marty C, Mori G, Sabini L, Rivarola V.

Biocell. 2000 Apr;24(1):49-52.

PMID:
10893799
14.
15.

APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.

Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, Gerner EW.

Carcinogenesis. 1999 Sep;20(9):1709-13.

16.

Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.

Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW.

J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30.

PMID:
8028034
17.

Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine.

Bacchi CJ, Garofalo J, Ciminelli M, Rattendi D, Goldberg B, McCann PP, Yarlett N.

Biochem Pharmacol. 1993 Aug 3;46(3):471-81.

PMID:
8347171
18.

Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.

Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H.

Cancer Res. 2000 Sep 15;60(18):5125-33.

20.

Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells.

Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW.

J Biol Chem. 2004 Jun 25;279(26):27050-8. Epub 2004 Apr 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk